Fabino Enterprises Limited

543444

INE0DRT01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 16/07/2024 BST			5-day change	1st Jan Change
29.75 ^INR	-4.98%		-14.59%	+8.18%

06-20	Fabino Life Sciences Changes Name to Fabino Enterprises	MT
05-28	Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Fabino Life Sciences Limited Announces Change in Registered Office Address

July 29, 2023 at 10:36 am

Fabino Life Sciences Limited informed that with effect from July 25, 2022, the new Registered Office of the Company is Jeevan Vihar Extension, Near Shubham Garden, Murthal Road, Sonipat, Haryana-131001.

Latest news about Fabino Enterprises Limited

Fabino Life Sciences Changes Name to Fabino Enterprises	06-20	MT
Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-28	CI
Fabino Life Sciences Limited Approves Executive Changes	12-26	CI
Fabino Life Sciences Limited Approves Change in Designation of Aditya Mahavir Jain from Non?Executive Director to Managing Director	12-26	CI
Fabino Life Sciences Managing Director Steps Down	12-26	MT
Fabino Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-13	CI
Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	18/08/23	CI
Fabino Life Sciences Limited Announces Incorporation of Wholly Owned Subsidiary	31/07/23	CI
Fabino Life Sciences Limited Announces Change in Registered Office Address	29/07/23	CI
Fabino Life Sciences Limited Announces Executive Changes	02/05/23	CI
Fabino Life Sciences Limited Announces Resignation of Aslam Mohammad as Company Secretary and Compliance Officer	25/04/23	CI
774,000 Equity Shares of Fabino Life Sciences Limited are subject to a Lock-Up Agreement Ending on 2-FEB-2023.	01/02/23	CI
Fabino Life Sciences Turns to Profit in Fiscal H1; Shares Jump 6%	24/11/22	MT
Fabino Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2022	09/11/22	CI
Fabino Life Sciences Limited Appoints Aslam Mohamrnad as Company Secretary and Compliance Officer	12/08/22	CI
Fabino Life Sciences Limited Announces Resignation of Jeel Poshiya as Company Secretary and Compliance Officer, Effective August 04, 2022	04/08/22	CI
Fabino Life Sciences Limited Announces Shifting of Registered Office	02/07/22	CI
Fabino Life Sciences Limited Appoints Sumit Malik as Additional Director (Non-Executive)	24/05/22	CI
Fabino Life Sciences Limited has completed an IPO in the amount of INR 32.4 million.	10/01/22	CI
Fabino Life Sciences Limited has filed an IPO.	26/11/21	CI

Chart Fabino Enterprises Limited

Duration

Period

More charts

Company Profile

Fabino Enterprises Limited, formerly Fabino Life Sciences Ltd, is an India-based pharmaceutical company. It offers a range of allopathic and herbal products. Its product categories include allopathic products, Covid-19 products, food supplements, herbal products, multi-vitamin products, and veterinary products. Its allopathic products include AMOXRAG-625, Astrid Syrup, Aurceta AM, Aurifox OZ, Aurirug 200, Aurirug O, Aurnim Plus, Aurstin 250, Ceporag O, Doref M, Dr-DSR, F Plexus A, and Fabpara. Its Covid-19 products include disposable face shield, fabclean hand sanitizer, mask and personal protective equipment (PPE). Its herbal products include Aurcis-Forte, Aurzyme-Syrup, Ayush Kadha, Coptec-syrup, DStoren-Syrup, Ecstasy Tilla Oil, Fablactin, Giloy Power, Keepshine Hair Oil, Onion Hair Oil, Pain-Go, Power Malt, Regaliv-ds, Sandy Forte and M-Sharp-Brain-tonic. Its multi-vitamin products include Aur D3 Capsules, Coptec Capsules, FABZYM CAPSULE, Oshnine Plus, and Rigovit Softgel Capsules.

Sector

Pharmaceuticals

Calendar

05/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FABINO ENTERPRISES LIMITED	+8.18%	787K
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.93%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.62%	244B
ROCHE HOLDING AG	+4.91%	234B
NOVARTIS AG	+16.19%	226B
AMGEN INC.	+14.63%	177B